台康生技 (6589.TWO)

79.90 -0.10 (-0.12%) 收市：01:30PM CST

台康生技

No. 101, Kangning Street
Lane 169 Xizhi District
New Taipei City
Taiwan
886 2 7708 0123
https://www.eirgenix.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Lee-Cheng Liu	Founder, President, CEO, CSO & Chairman	10.17M	無	無
Ms. Hsiu-Chuan Yang	CFO, VP & Manager of Corporate Governance	8.1M	無	無
Dr. Chih-Jung Chang	VP & COO	7.3M	無	無
Dr. Thomas Schulze Ph.D.	Managing Director of EirGenix Europe GmbH	無	無	無
Dr. Shang-Chung Ju	Executive Director & Chief Manufacturing Officer	無	無	無

截止 2021年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. EirGenix Inc. was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.

公司管治

截至 無 止，台康生技 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。